Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

NCT00510354 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Gastrointestinal Stromal Tumor

Interventions

DRUG: Imatinib mesylate

Sponsor

Novartis Pharmaceuticals